Navigation Links
Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
Date:10/19/2011

CAGR) of 24.7% to reach $1.6 billion in 2018. Benlysta (belimumab) was approved on March 9, 2011 by the US Food and Drug Administration (FDA) and on July 14, 2011 by the European Medicine Evaluation Agency (EMEA) in Europe for treating adult patients with active, autoantibody-positive SLE. It the drug for SLE to be approved in 50 years and is expected to drive the SLE market in the near future. Furthermore, the entry of four first-in-class (FIC) biologics, Orencia (abatacept), atacicept, epratuzumab, LY2127399 is expected to play a major role in the expansion of the SLE market by 2018.

Scope

The report provides information on the key drivers and challenges of the SLE market. Its scope includes -

- Annualized seven key SLE market (US, France, Germany, Italy, Spain, UK and Japan) revenue data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data showing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under the following major therapeutic classes: anti-BAFF (B-cell activating factor), immunomodulator, anti-IFN-alpha, Toll-Like Receptor TLR7/TLR9 inhibitor, CD22 antigen Inhibitor, T-cell co-stimulation modulator and calcineurin inhibitor.

- Analysis of the current and future competition in the global SLE market. Key market players covered are Anthera Pharma, AstraZeneca PLC/MedImmune LLC, Active Biotech AB, Amgen Inc., Bristol-Myers Squibb Co., Biotest AG, Cephalon, Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd/Genentech, Johnson & Johnson/Centocor, Inc, Merck KGaA/Merck Sereno, MedImmune, LLC, Neovacs SA, Onyx Pharmaceuticals and UCB Group/Immunomedics Inc.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, u
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis
2. Pevions Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
3. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
4. Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018
5. Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus
6. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
7. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
8. Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate
9. Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus
10. Promise of a New Lupus Treatment Is a Groundbreaking Achievement
11. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Telbec/ - Mirego, leader in mobile strategies and solutions, is ... app extensions for the all new Apple Watch. Made in ... and MediaMiser, these extensions will reinvent the way users receive ... wrist use.  Available today in ... tactile smartwatch that makes for an excellent buddy for business, ...
(Date:4/23/2015)... 24, 2015 Ralco announced today that ... Nutrition® (ABN) for the exclusive worldwide rights to sell ... technology is a new in-line milk system that increases ... them to move supplementation milk cups within a farrowing ... “This technology lets producers get Birthright™ milk to the ...
(Date:4/23/2015)... Fla. , April 23, 2015 BioTE ... releases his book "Age Healthier Live Happier - Avoiding ... off the Age Management Medicine Group Conference at JW ... 26, 2015. ",Age Healthier Live Happier, is ... to avoid over-medication and searching for a higher quality ...
(Date:4/23/2015)... 2015 Follow us on ... series of genetic tests that determine individual susceptibility ... disease, Huntington's disease, and Alzheimer's disease. Predictive diagnostics ... and interaction in diseased tissue/cells to understand and ... the response to treatment, such as in the ...
Breaking Biology Technology:Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2Ralco Acquires License to Birthright™ Moveable Milk Cup 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3
... Scientists engaged in biological research and drug discovery are ... BioInformatics, LLC ( www.gene2drug.com ), the premier research ... released preliminary data from the company,s newest report ... Science Suppliers. In this report, we set out ...
... LOUIS, Feb. 11 Sigma-Aldrich, a leading Life,Science and High ... by 6% to $0.68 from $0.64 in the same quarter ... $510 million in the fourth quarter 2008 declined by 4%,compared ... fourth,quarter grew 3% from a year ago. Fourth quarter organic ...
... Development for Chronic Pain IndicationsLA JOLLA, Calif., Feb. ... TPTX ) today announced that oral administration of ... and well-tolerated in healthy male and female subjects ... successful completion of this Phase I trial demonstrating ...
Cached Biology Technology:Life Science Labs Reacting to the Economic Crisis 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 3Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 4Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 5Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 6Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 7Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 8Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 9Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 10Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 11Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 12Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 13First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore ... key protein linked to stem cell-like behavior in terminal-stage ... drugs that may extend the survival of these patients. ... Proceedings of the National Academy of Sciences , ...
... to reduce by more than half the time it takes ... researchers in Penn State,s College of Agricultural Sciences. The finding ... foodborne illness, allowing epidemiological investigators to identify the exact strains ... more quickly find -- and eliminate -- the source of ...
... long been used for various purposes, like cleaning wastewater at ... handcrafted wickerwork, as means of nutrition and, in traditional medicine, ... Fraunhofer Institute for Building Physics IBP in Valley now want ... to wit, for the insulation of outer walls or ...
Cached Biology News:Singapore research team identifies new drug target in deadly form of leukemia 2Researchers develop a faster method to identify Salmonella strains 2Researchers develop a faster method to identify Salmonella strains 3Using cattails for insulation 2Using cattails for insulation 3
Request Info...
Preparation Note: by a modification of the procedure of C.W. Hancher et al., Biotechnol. Bioeng. 11, 1055 (1969) Assay: ~ 20 A 260 /mg Solubility: water 10 mg/mL, clear, light-yellow Suitab tst...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... The Microarray Gene Frame® has ... hybridisations. These frames feature the same ... standard Gene Frame® range for easy ... hybridisation uniformity and there are three ...
Biology Products: